Multiple redox and inflammatory proteins

Multiple redox and inflammatory proteins refers to a broad set of downstream effectors that are coordinately regulated to maintain cellular homeostasis and resolve inflammation [1][2]. This term is primarily used in the context of drugs that modulate the Keap1-Nrf2 (Nuclear factor erythroid 2-related factor 2) and NF-κB (Nuclear factor kappa-light-chain-enhancer of activated B cells) signaling pathways [1][4]. Activation of Nrf2 leads to the up-regulation of antioxidant and detoxifying enzymes, such as heme oxygenase-1 (HO-1) and NAD(P)H:quinone oxidoreductase 1 (NQO1), while inhibition of NF-κB reduces the production of pro-inflammatory cytokines [2]. This dual action aims to restore mitochondrial function and reduce oxidative stress in chronic diseases [1]. However, because this designation encompasses a wide variety of proteins rather than a single molecular target, it is considered a descriptive category of a drug's pharmacodynamic effect rather than a canonical therapeutic target entity [1][3]. Clinical applications include the treatment of chronic kidney disease, Alport syndrome, and Friedreich's ataxia, though systemic modulation of these pathways requires monitoring for safety concerns such as fluid retention and cardiovascular stress [3][5].

Other names

Redox-sensitive proteinsInflammatory mediatorsNrf2-regulated proteinsNF-κB-regulated proteinsAntioxidant response element (ARE) proteins

Modulation of these proteins is achieved through the activation of the Nrf2 pathway and inhibition of the NF-κB pathway, typically by targeting the Keap1 protein to induce antioxidant gene expression and suppress pro-inflammatory signaling [1][2].